Janney Capital Maintains Buy On Vertex Ahead Of 2Q:14 Earnings Results
In a research report published today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Vertex Pharmaceuticals (VRTX) with a $110 price target, which represents 12% upside to the current share price.
Lee noted, “We forecast 2Q revenue of $124.1 million and EPS of $(0.91) versus consensus of $132.7 million and $(0.73), respectively. We expect additional color on Kalydeco growth in the EU along with label expansion plans. Importantly, we anticipate a pipeline update, specifically on VX-661 and the company’s plans for the program”.
According to TipRanks.com, which measures analysts and bloggers success rate based on how their calls perform, analyst Kimberly Lee currently has a one-year average return of 12.0% and a 53% success rate. Lee has a 28.7% average return when recommending VRTX, and is ranked #970 out of 3213 analysts.